Transparent Public Pricing for Biosimilars: pCPA Releases First Principles for SEBs

Guest Blog By Arvind Mani Director of Market Access and Policy Research PDCI Market Access The pan-Canadian Pharmaceutical Alliance (pCPA) recently issued a communiqué outlining their initial perspective on subsequent entry biologics (SEBs) and innovative/reference biologics as it aims to establish a SEB policy framework.  Key Takeaways It appears that the pCPA’s first principles for SEBs

Feds Take a Seat at the pCPA Table

Reposted with permission from the author, Arvind Mani.  On January 20-21, 2016, the provincial Ministers of Health met in British Columbia to discuss health care priorities and were joined for their second day of meetings by Canada’s new federal Minister of Health, Jane Philpott.  At the conclusion of their meetings, it was announced that the federal government will